New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

US FDA Decision Expected 1 December

 
• By Andrew McConaghie
  
Roche_Logo_Glass
Roche's Tecentriq is trailing Merck's Keytruda in advanced NSCLC, but could be first approved in an adjuvant setting.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip